Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Stock: A Perfect Dip for Investors to Buy
12:46pm, Wednesday, 03'rd Jul 2024
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & John
AbbVie Stock: A Perfect Dip for Investors to Buy
12:45pm, Wednesday, 03'rd Jul 2024
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & John
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
04:45pm, Tuesday, 02'nd Jul 2024
Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more.
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
08:00am, Tuesday, 02'nd Jul 2024
NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens.
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
06:24am, Tuesday, 02'nd Jul 2024
One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.
3 Retirement All-Stars for Steady Growth and Income
04:30pm, Monday, 01'st Jul 2024
Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
10:48am, Monday, 01'st Jul 2024
The S&P 500 index is up, but not all of its components participated in the rally. Shares of Pfizer have fallen over the past year, and the stock offers a dividend yield now that's much larger than usu
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
09:40am, Monday, 01'st Jul 2024
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
08:00am, Monday, 01'st Jul 2024
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A.
3 Magnificent Stocks Retirees Can Buy and Hold Forever
06:50am, Monday, 01'st Jul 2024
AbbVie is a Dividend King poised for growth. Gilead Sciences is a stable, low-risk candidate for investors.
If I Had To Retire With 10 Dividend Aristocrats, It Would Be These
10:35am, Sunday, 30'th Jun 2024
If you want a massive dividend snowball: Get the right combination of dividend yield and growth for maximum compounding effect. Dividend Aristocrats may not always be the best choice due to high valua
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
09:55am, Friday, 28'th Jun 2024
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follic
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
12:06pm, Thursday, 27'th Jun 2024
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
10:06am, Thursday, 27'th Jun 2024
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
